Roundhill GLP-1 & Weight Loss ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Roundhill Glp-1 & Weight Loss ETF OZEM
Morningstar’s Analysis OZEM
Will OZEM outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 65.1
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Novo Nordisk AS ADR | 12.81 | 8M | Healthcare |
Eli Lilly and Co | 12.45 | 8M | Healthcare |
Pfizer Inc | 6.18 | 4M | Healthcare |
Kailera Therapeutics Inc | 5.94 | 4M | Healthcare |
Viking Therapeutics Inc | 5.81 | 4M | Healthcare |
CSPC Pharmaceutical Group Ltd | 5.79 | 4M | Healthcare |
Ascletis Pharma Inc Ordinary Shares | 4.29 | 3M | Healthcare |
Chugai Pharmaceutical Co Ltd | 4.24 | 3M | Healthcare |
Amgen Inc | 3.78 | 2M | Healthcare |
Zealand Pharma AS | 3.78 | 2M | Healthcare |